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Abstract
The Netherlands is known for its low methicillin-resistant Staphylococcus aureus (MRSA) prevalence. Yet MRSA with no link to estab-
lished Dutch risk factors for acquisition, MRSA of unknown origin (MUO), has now emerged and hampers early detection and control
by active screening upon hospital admittance. We assessed the magnitude of the problem and determined the differences between
MUO and MRSA of known origin (MKO) for CC398 and non-CC398. National MRSA Surveillance data (2008–2009) were analysed for
epidemiological determinants and genotypic characteristics (Panton–Valentine leukocidin, spa). A quarter (24%) of the 5545 MRSA iso-
lates registered were MUO, i.e. not from defined risk groups. There are two genotypic MUO groups: CC398 MUO (352; 26%) and
non-CC398 MUO (998; 74%). CC398 MUO needs further investigation because it could suggest spread, not by direct contact with live-
stock (pigs, veal calves), but through the community. Non-CC398 MUO is less likely to be from a nursing home than non-CC398 MKO
(relative risk 0.55; 95% CI 0.42–0.72) and Panton–Valentine leukocidin positivity was more frequent in non-CC398 MUO than MKO
(relative risk 1.19; 95% CI 1.11–1.29). Exact transmission routes and risk factors for non-CC398 as CC398 MUO remain undefined.
Keywords: Community, epidemiology, livestock, methicillin-resistant Staphylococcus aureus, Panton–Valentine leukocidin, policy,
prevention and control, risk, surveillance, the Netherlands
Original Submission: 3 June 2011; Revised Submission: 19 August 2011; Accepted: 24 August 2011
Editor: G. Lina
Article published online: 30 August 2011
Clin Microbiol Infect 2012; 18: 656–661
10.1111/j.1469-0691.2011.03662.x
Corresponding author: M. C. Vos, Department of Medical
Microbiology and Infectious Diseases, Erasmus MC, University
Medical Centre, Postbus 2040, 3000 CA Rotterdam, the Netherlands
E-mail: m.vos@erasmusmc.nl
Introduction
In the past 20 years, the Netherlands kept methicillin-resis-
tant Staphylococcus aureus (MRSA) at bay through prudent use
of antibiotics and a Search and Destroy policy. Part of Search
and Destroy is active detection and isolation based on
defined risk groups. For these reasons, MRSA prevalence in
Dutch hospitals and community is still low [1,2]. The Dutch
Working party on Infection Prevention developed a guideline
on MRSA prevention. (Table 1) This guideline defines the
national risk groups and the procedure of contact tracing
around cases is described. The Dutch policy can therefore be
seen as targeted surveillance on defined risk groups. How-
ever, MRSA was found in people who were not targeted by
the Search and Destroy policy because they did not belong
to the defined risk groups [3]. In the present study, these
cases are defined as ‘MRSA of unknown origin’ (MUO).
MUO can transmit, until detection, because preventive mea-
sures are not taken. To enable the targeting of control strat-
egies for MUO, the magnitude of the problem was measured
and the differences were determined between MUO and
MRSA of known origin (MKO; comprising MRSA risk groups
and contact tracing described in the targeted surveillance).
Materials and Methods
Data from the national MRSA surveillance database at the
National Institute for Public Health and Environmental
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Protection (RIVM) between 1 January 2008 and 31 Decem-
ber 2009 were used. All MRSA strains sent to the RIVM by
68 Dutch laboratories, covering the whole country, are reg-
istered in this database. Of the cultures positive for MRSA
taken from a single person, one, usually the first detected,
strain is sent to the RIVM. A check on duplicates in the data-
base further ensured one MRSA strain per person. At the
RIVM the MRSA strains were confirmed by testing for the
presence of the mecA gene and the coagulase gene. For all
confirmed MRSA the spa-type, as described by Harmsen
et al. [4], and the presence of the Panton–Valentine leukoci-
din gene (PVL-gene) were determined [5]. As there was no
significant difference in the number and data of reported iso-
lates and carriers between the 2 years, data were pooled to
increase power.
Based on spa-types we distinguished CC398 (livestock-
associated strains) and non-CC398 [6]. CC398 was checked
by RIVM with multiple-locus variable number tandem repeat
analysis (http://www.mlva.net/). CC398 was analysed as a
separate group from non-CC398. Each strain was submitted
with a form, with background information on hospital, demo-
graphic patient information, risk factors when applicable
(Table 1), and other relevant epidemiological information.
Laboratories were approached by the RIVM to complete
their missing data as much as possible. Two defined groups,
MUO and MKO, were classified based on the included infor-
mation on defined risk factors requested. The absence of
either defined risk factors or of risk factors found through
contact tracing, led to a classification of MUO. Additional
remarks were usually made on the form and/or the box for
‘Unknown MRSA’ was ticked. Isolates with no or incomplete
additional epidemiological data (No data), which made classi-
fication impossible, were not included in further descriptive
and multivariate analysis. Finally, additional remarks on the
form were categorized to gain insight into new sources and
risk factors.
The most prevalent spa-types were determined for the
total amount of MRSA, CC398, non-CC398 MRSA, MUO
and MKO. The spa-types were ranked with rank 1 being the
most prevalent spa-type within the (sub)group; rank 2 the
second most prevalent, etc.
SAS statistical software (ENTERPRISE GUIDE version 4.2) was
used for descriptive analysis, univariate analysis (Fisher’s
exact test) and multiple regression analysis (log-binomial
regression model, proc GENMOD). A p value of <0.05 was
considered significant. Goodness of fit was determined with
the area under the curve of a receiver operating characteris-
tic-curve (ROCR software). Relative risks (RR) with 95% CI
were calculated.
Results
General results
In 2 years, 5545 MRSA strains were sent to the reference
laboratory and so were available for analysis: 2671 reported
in 2008 and 2874 in 2009. From the 5545 MRSA, 3233
(58%) were non-CC398 and 2312 (42%) were CC398 (live-
stock-associated MRSA). The MUO and MKO proportions
of these groups were determined (Table 2).
TABLE 1. Dutch defined risk groups
Risk groups Numbers (%)
Patient risk group (n = 2538)a
Contact with roommates or carrier
Single room shared with MRSA carrier 89 (4%)
Contact tracing 485 (19%)
Foreign
Cared for in a foreign hospital 342 (13%)
Foreign patients at a Dutch dialysis department 1 (0.04%)
Adopted children: hospitalized or frequently visit
the outdoor department
62 (2%)
Dutch dialysis patients dialysed abroad 1 (0.04%)
Livestock
Work-related contact with live pigs or veal calves 1120 (44%)
Outbreak
Patients from another Dutch hospital or nursing
home, from a department
or unit where there is an MRSA outbreak, which
is not under control
128 (5%)
MRSA carrier
Proven carrier 119 (5%)
Healthcare workers risk group (n = 255)a
Contact with roommates or carrier
Unprotected contact without infection precautions 165 (64%)
Protected contact with infection precautions 19 (7%)
Contact tracing 33 (13%)
Foreign
Cared for in a foreign hospital 2 (0.8%)
Worked <2 months ago, but longer than 24 h in
a foreign hospital or nursing home
10 (4%)
Worked (regularly) in a hospital abroad or escorted
patients from a foreign to a Dutch hospital
7 (3%)
Livestock
Work-related contact with live pigs or veal calves 1 (0.4%)
MRSA carrier
Proven carrier 5 (2%)
MRSA, methicillin-resistant Staphylococcus aureus
aMRSA in the Netherlands in 2008–2009. A single carrier can have more than
one risk.
TABLE 2. MUO and MKO proportions among MRSA
MUO (%) MKO (%) No dataa (%)
Total
MRSA
Non-CC398 998 (30.9) 1407 (43.5) 828 (25.6) 3233
CC398 352 (15.2) 1386 (59.9) 574 (24.8) 2312
Total MRSA 1350 (24.3) 2793 (50.3) 1402 (25.3) 5545
MUO, methicillin-resistant Staphylococcus aureus (MRSA) of unknown origin;
MKO, MRSA of known origin; CC398, livestock-associated MRSA.
Data are from the Netherlands over a 2-year period (2008–2009).
aExcluded from analysis.
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Molecular results
A total of 403 different spa-types were identified and 13
strains were not typeable. Five spa-types constituted 51% of
the total MRSA, i.e. t011, t108, t008, t002 and t064. Among
non-CC398, 364 different spa-types were identified, of which
210 were MUO and 209 were MKO. For CC398, there
were 40 different spa-types, of which 17 spa-types were
MUO and 26 were MKO (see also Tables 3 and 4). The spa-
types t008 (ST8), t019 (ST30) and t044 (ST80) were more
often found among non-CC398 MUO than among MKO
(p <0.01) and type t034 (CC398) was more often found
among CC398 MKO than CC398 MUO (p <0.01).
Of all MRSA, 684 (12%) were PVL-positive. For non-
CC398 MUO this was 461 (46%), for non-CC398 MKO it
was 144 (10%) and for CC398 MKO it was 3 (0.2%) (see
also Table 5). There were significantly more PVL-positive
t008 (USA300) among non-CC398 MUO (106 events, 10.6%
of total MUO), than among non-CC398 MKO (38 events,
1.7% of total MKO) (p <0.01).
Comparing CC398 MUO with non-CC398 MUO
Of the 998 non-CC398 MUO, 745 (75%) had added
remarks on the form. Of the remarks, 101 (14%) were
related to (health) care, 104 (14%) to foreigners (contact
with a foreigner or being one), 95 (13%) to contact with a
positive family member and no indication for a possible
source was obtained from 253 (34%). Of the 352 CC398
MUO, 300 had added remarks (85%). Fifty (17%) were
attributed to a link with animals in general, of which 16
were through a positive relative; 28 (9%) were linked to a
positive family member not involved with any animals, and
197 (66%) had no indication for a possible source. Pigs were
the specifically mentioned animals for half of the animal-
related events (26; 52%), followed by bovids (9; 14%, seven
cattle, one goat, one sheep), horses (6; 12%) and chickens
(3; 6%).
Epidemiological characteristics
The following determinants were positively associated with
non-CC398 MUO after univariate analysis: age (£20 years),
being a male hospital patient, household (the location where
the MRSA carrier resided at the time of detection), clinical
isolates, three spa-types (t008, t019 and t044) and four
Dutch provinces, (Table 5) whereas for CC398 MUO, these
were age (‡65 years), patient, household, clinical isolates
(but not blood) and three Dutch provinces (Table 5).
TABLE 3. Most prevalent spa-types in the Netherlands
Rank
Non-CC398 CC398
MRSA
(n = 5545)
Total
(n = 3233)
MUO
(n = 998)
MKO
(n = 1407)
Total
(n = 2312)
MUO
(n = 352)
MKO
(n = 1386)
Spa % Spa % Spa % Spa % Spa % Spa % Spa %
1 t011 24 t008 14 t008 17 t008 10 t011 59 t011 59 t011 59
2 t108 11 t002 8 t002 8 t002 8 t108 26 t108 27 t108 26
3 t008 8 t064 5 t019 6 t064 6 t034 4 t567 2 t034 4
4 t002 5 t032 4 t044 5 t179 5 t567 2 t571 2 t899 2
5 t064 3 t044 4 t064 3 t032 4 t899 2 t899 2 t567 2
MUO, methicillin-resistant Staphylococcus aureus (MRSA) of unknown origin; MKO, MRSA of known origin; CC-398, livestock-associated MRSA.
Data are from the Netherlands over a 2-year period (2008–2009). The five most prevalent spa-types are shown for the total amount of MRSA, non-CC398 and CC-398 dis-
tribution. The last two (non CC398 and CC398) have a subdivision in MUO and MKO. Rank 1 means first most prevalent spa-type, rank 2 means second most prevalent
spa-type, etc. Percentages are of group totals (mentioned with n). In total, 403 different spa-types were typed (out of 5565 MRSA).
TABLE 4. Comparison of most prevalent spa-types in the Netherlands
Spa-type
Non-CC398 CC398
MRSA
(n = 5545)
Total
(n = 3233)
MUO
(n = 998)
MKO
(n = 1407)
Total
(n = 2312)
MUO
(n = 352)
MKO
(n = 1386)
Spa % Spa % Spa % Spa % Spa % Spa % Spa %
t032 6 2 4 4 9 2 5 4 – – – – – –
t044 7 2 5 4 4 5 16 2 – – – – – –
t019 8 2 6 3 3 6 14 2 – – – – – –
t179 10 2 8 3 16 1 4 5 – – – – – –
t034 11 1 – – – – – – 3 4 6 1 3 4
t571 28 0.5 – – – – – – 7 1 4 2 8 1
MUO, methicillin-resistant Staphylococcus aureus (MRSA) of unknown origin; MKO, MRSA of known origin; CC-398, livestock-associated MRSA.
Spa-types mentioned in Table 2 as most prevalent for one group, but not found in a top five for one of the other groups in Table 2, can be compared in this table for its
prevalence in other groups. Rank 1 means first most prevalent spa-type, rank 2 means second most prevalent spa-type, etc. A dash means the spa-type was not present
within the specific group. Data are from the Netherlands over a 2-year period (2008–2009).
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The log-binomial regression model, comprised four deter-
minants (PVL, person, healthcare centre and source of speci-
men; Table 5), with an area under the curve of 0.81 (figure
not shown) for non-CC398 and three determinants (source
of specimen, age and provinces), with an area under the
curve of 0.66 (figure not shown). There was no further sig-
nificant effect when adding other determinants to the model.
The strongest determinant associated with non-CC398
MUO was PVL positivity (RR 1.19; 95% CI 1.11–1.29). For
CC398 MUO, this was age (20–65 years: RR 0.73; 95% CI
0.59–0.90).
In the healthcare centre group, the nursing home had a
lower risk for MUO in comparison with the other group
(comprising revalidation centres and various other healthcare
institutions) with an RR of 0.55 (95% CI 0.42–0.72). For
nose, throat and perineum samples, there was a lower risk
associated with MUO (RR 0.45; 95% CI 0.0–0.74). The risk
for a healthcare worker to be associated with non-CC398
MUO rather than with non-CC398 MKO was greater in
comparison with the risk for patients (Table 5).
Discussion
Of the 5545 MRSA isolates registered during 2008 and 2009,
24% were not found by targeted surveillance. The Nether-
lands has a CC398 MUO group (352; 26%) and a non-
CC398 MUO group (998; 74%). The primary conclusion
from the regression model was that PVL-positive MRSA was
more frequent in non-CC398 MUO than MKO (RR 1.19;
95% CI 1.11–1.29) and that non-CC398 MUO was less likely
to come from a nursing home than MKO (RR 0.55; 95% CI
0.42–0.72).
Only a small portion of the CC398 MUO had a described
link to animals and was not defined in the risk groups for
MKO (50; 17%). Animals mentioned were bovids, horses and
chickens. It remains unclear whether there was any relation of
these MUO to livestock-related work. It is known that live-
stock-associated MRSA CC398 is not only found in pigs, but
also in cattle, calf farmers, horses, horse personnel, poultry,
slaughterhouse personnel and rats [7–12]. Remarks on the
TABLE 5. Epidemiological data on non-CC398 and CC398 MRSA in the Netherlands
Characteristics
Non-CC398 CC398
MUO
(n = 998)
MKOa
(n = 1407)
Univariate
analysis
p value
Multiple regression
MUO
(n = 352)
MKOa
(n = 1386)
Univariate
analysis
p valueRR (95% CI) p value
Sex
Male 530 (53%) 594 (42%) <0.01 – – 219 (62%) 917 (66%) 0.16
Female 452 (45%) 768 (55%) <0.01 – – 133 (38%) 469 (34%) 0.16
Age
£20 years 161 (16%) 173 (12%) <0.01 – – 50 (14%) 163 (12%) 0.21
20–65 years 543 (54%) 769 (54%) 0.94 – – 227 (64%) 1086 (78%) <0.01e
‡65 years 294 (29%) 465 (33%) 0.07 – – 75 (21%) 137 (10%) <0.01
Person
Patient 981 (98%) 1188 (84%) <0.01 – – 351 (99%) 1350 (97%) <0.01
Healthcare worker 17 (2%) 219 (16%) <0.01 3.21 (2.09–5.33) <0.01 1 (0.3%) 36 (3%) <0.01
Healthcare centre
General hospital 523 (52%) 662 (47%) 0.01 0.96 (0.86–1.12) 0.58 218 (62%) 1011 (73%) <0.01
Academic hospital 102 (10%) 155 (11%) 0.55 0.95 (0.81–1.13) 0.58 23 (7%) 59 (4%) 0.07
Categorical hospital 6 (1%) 4 (0.3%) 0.34 0.98 (0.54–1.26) 0.91 0 (0%) 2 (0.1%) 1.00
Nursing home 52 (5%) 259 (18%) <0.01 0.55 (0.42–0.72) <0.01 2 (0.6%) 17 (1%) 0.29
Unknown 20 (2%) 32 (2%) 0.67 0.92 (0.66–1.17) 0.56 8 (2%) 14 (1%) 0.06
Household 226 (23%) 200 (14%) <0.01 1.08 (0.97–1.25) 0.21 78 (22%) 223 (16%) 0.01
Otherb 69 (7%) 95 (7%) 0.87 – – 23 (7%) 60 (4%) 0.08
Source of specimenc
Nose, throat, perineum 278 (28%) 1083 (77%) <0.01 0.45 (0.0–0.74) <0.01 233 (66%) 1229 (89%) <0.01
Urine 66 (7%) 29 (2%) <0.01 1.31 (0.92–2.15) 0.20 6 (2%) 6 (0.4%) 0.01
Respiratory 54 (5%) 21 (1%) <0.01 1.32 (0.92–2.16) 0.20 19 (5%) 6 (0.4%) <0.01
Skin and soft tissue 392 (39%) 144 (10%) <0.01 1.31 (0.95–2.13) 0.18 42 (12%) 27 (2%) <0.01
Blood 18 (2%) 4 (0.3%) <0.01 1.44 (0.96–2.38) 0.10 2 (0.6%) 1 (0.1%) 0.05
Indwelling deviced 12 (1%) 12 (1%) 0.41 – – 2 (0.6%) 1 (0.1%) 0.05
Unknown 59 (6%) 85 (6%) 0.93 0.8 (0.54–1.34) 0.32 24 (7%) 97 (7%) 0.91
Other 119 (12%) 29 (2%) <0.01 1.35 (0.97–2.20) 0.14 24 (7%) 19 (1%) <0.01
Typing
PVL-positive 317 (68%) 144 (10%) <0.01 1.19 (1.11–1.29) <0.01 0 (0%) 3 (0.2%) 1.00
MUO, methicillin-resistant Staphylococcus aureus (MRSA) of unknown origin; MKO, MRSA of known origin; PVL, Panton–Valentine leukocidin; RR, relative risk.
These data are from the Netherlands over a 2-year period (2008–2009). CC398 is the livestock-associated cluster in the Netherlands.
aAs defined by the Dutch Working group of Infection Prevention. See also Table 1.
bRevalidation centre, prison, correctional facility, etc.
cOnly one strain is sent to the reference laboratory. These are the counts of the sources of the strains sent. No information is available for whether other sources were
positive as well. Therefore these numbers reflect the minimum.
dCatheters etc.
eThe only significant factor from the multivariate analysis, for CC398 MUO, was age (20–65 years old: RR 0.73; 95% CI 0.59–0.90).
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forms indicated that a specific link was not always found.
CC398 MUO needs further investigation as it could suggest
spread through the community not by direct contact with live-
stock. In 2009 Cuny et al. [13] concluded that the dissemina-
tion of MRSA CC398 (CC398) to non-exposed humans was
infrequent and probably did not reach beyond familial commu-
nities and a low human-to-human transmission was confirmed
in several studies [14–16]. Surveillance will remain necessary
to monitor livestock-associated MRSA evolution, its spread in
the surrounding (innate) environment and to detect new risk
factors or transmission routes. The possibility of increased
incidence of livestock-associated MRSA, and subsequently of
livestock-associated MRSA infections in the future, cannot be
ruled out. Overall, there was more MUO in Dutch provinces
without areas dedicated to intensive cattle breeding.
Three spa-types in the non-CC398 MUO group, t008 (ST-
8; North America, Europe and Southeast Asia [17,18]), t019
(ST-30; North America and Southeast Asia [17]) and t044
(ST-80; mainly found in Europe [19–21]), were found more
often among MUO than among MKO (Tables 3 and 4). Addi-
tion of these three spa-types to the regression model of
non-CC398 gave no significant effect in the presence of PVL.
By definition, we do not know where MUO come from.
MUO could be community-associated MRSA or comprise
one or several new risk groups or reservoirs.
A possible explanation for the PVL correlation with non-
CC398 MUO might be found in the association of young age
(children and young adults) with non-CC398 MUO (Table 5,
univariate). The literature reports that children and young
adults were a risk factor for community-associated MRSA
infections [22]. The CANWARD study described a trend
toward younger patient age for community-associated MRSA
genotypes [23]. At first the univariate analysis in this study
revealed a positive association with young age (£20 years) as
well, but its significant effect or trend was lost in the regression
model. Another difference between the two studies is that this
study defined MRSA MUO and MKO epidemiologically.
Surprisingly the regression model of non-CC398 showed
that it was less likely for (non-CC398) MUO to come from
a nursing home (Table 5) than MKO. Dutch MRSA preva-
lence in nursing homes is still low (<1%) [24], in contrast to
nursing homes in other parts of Europe (20%) and North
America (18.8–35.7%) [25]. For nursing homes, the Working
party on Infection Prevention also applies guidelines for gen-
eral precautions and in particular to prevent MRSA. It is
likely that, up to now, the Dutch nursing homes have not
served as a source for MRSA and, as far as we can conclude
from our data, nursing homes are not the source of MUO.
Previous research has shown that spread of MRSA within
households (not a risk group in the Working party on Infec-
tion Prevention ) was substantial [26]. Mollema et al. [26]
showed that the transmission of MRSA from an index person
to household contacts occurred in nearly half of the cases,
and two-thirds of household contacts became MRSA posi-
tive. Yet in the regression model for non-CC398 the deter-
minant household lost its significance. In our Search and
Destroy policy, eradication is one of the cornerstones for
keeping rates low [3,27]. If detected MRSA carriers were
not offered eradication therapy, this would allow further
spread, presumably in the household or through other close
contacts.
The early opportunity to eradicate MUO and to interrupt
its transmission (according to the Search and Destroy policy)
is missed, because MUO are not actively cultured for the
presence of carriage [3,27]. Considering the amount of
MUO, this would be at least 24% of the total MRSA in the
Netherlands.
It is important to realize that MUO are not targeted by
the risk groups for active detection and isolation and go
unnoticed until they are unexpectedly detected from a clini-
cal sample. This explains the significantly higher MUO pro-
portion found in clinical specimens, compared with MKO
from persons who were actively screened. This gives a possi-
ble second explanation for the PVL correlation with non-
CC398 MUO, but also suggests that the unexpected MUO
found so far are the tip of an iceberg.
Exact transmission routes and risk factors for MUO are,
for now, obscure, although there is an indication that the
community is a source of non-CC398 MUO. In addition,
remarks on the forms for non-CC398 that are returned to
the RIVM indicate having a foreign origin or having been
abroad without having visited a hospital or having foreign
relatives, which are all in line with studies reporting immi-
gration as a risk factor [21,28]. Although cross-dissemination
as a result of past foreign hospital visits, longer than
2 months before admission to a Dutch hospital, could also
play a role [29].
The small proportion of CC398 MUO needs further
research to see whether community spread indeed happens,
despite the current dogma of no spread outside the risk
population, because of person-to-person transmission or
spread as a food-borne pathogen [30].
In conclusion, at least a quarter of the total Dutch MRSA
is not from the defined risk groups. Studies on new sources
and transmissions are urgently needed to possibly update the
guidelines and to keep the MRSA prevalence low. Further-
more, Search and Destroy policy should be evaluated on
their defined risk groups and the number of MUO. These
are essential steps to take in order to cope with the dynamic
nature of Staphylococcus aureus and its changing epidemiology.
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